NCS Multistage Holdings Inc NCSM Q1 2026 Earnings EPS Misses Estimates Significantly Revenue Data Unavailable PROK Q1 2026 Earnings Narrow Loss Beat Highlights Steady Progress in Cell Therapy Pipeline CMPS Q1 2026 Earnings Loss Narrower Than Expected as Company Advances Clinical Pipeline NJR Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency and Regulatory Execution Ernexa Therapeutics ERNA Q3 2023 Earnings ClinicalStage Biotech Reports Net Loss as Stock Declines TLK Q4 2025 Earnings Significant EPS Miss Sends Shares Lower